Reynold A. Panettieri Jr, MD

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide.

The value of the combination of albuterol/budesonide is high due to its alleviating of corticosteroid burden, according to Reynold Panettieri Jr, MD.

Reynold A. Panettieri Jr., MD, examines the application of biologic therapies in the treatment of respiratory conditions.

A key opinion leader explores therapeutic approaches targeting inflammation to alleviate symptoms in COPD and asthma patients.

An expert in COPD delves into biomarkers indicative of type 2 inflammation and recommends diagnostic tests for assessing inflammation in COPD patients.

Reynold A. Panettieri Jr., MD, elaborates on the risks of lung damage resulting from exacerbations, with a focus on the role of type 2 inflammation in triggering these events.

A key opinion leader examines the etiology of asthma and potential risk factors for COPD development, emphasizing the role of environmental exposures.

Reynold A. Panettieri Jr., MD, explores the impact of COPD and asthma on patients' quality of life, highlighting exercise limitations and sleep disturbances.